Skip to main content
SpringerLink
Log in
Book cover

Diagnostic Molecular Pathology in Practice pp 123–131Cite as

Myeloproliferative Neoplasms

  • Chapter
  • First Online:

  • 2255 Accesses

Abstract

A 59-year-old female was referred to the hematology department for evaluation of persistent erythrocytosis. Two years prior to this visit, she was seen by her primary care physician with complaints of intermittent mild night sweats, frequent vasomotor symptoms such as hot flashes, and early satiety with abdominal fullness and pain if she laid on her right side. Laboratory evaluation at that time revealed a hematocrit of 57.6% (reference interval 38.5–49%), hemoglobin of 18.3 g/dL (reference interval 13.2–16.9 g/dL), and red blood cell count of 7.0 ?× ?106/?L (reference interval 4.5–5.1 ?× ?106/?L). She was treated with phlebotomy alone for approximately two years. However, she continued to have persistent erythrocytosis and during her last checkup was found to have an elevated platelet count of 915,000/?L (reference interval 150,000–450,000/?L).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Levine RL, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190–2198

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Spivak JL (2010) Narrative review: thrombosis, polycythemia vera, and JAK2 mutations: the phenotypic mimicry of chronic myeloproliferation. Ann Intern Med 152:300–306

    Article  PubMed  Google Scholar 

  3. James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148

    Article  PubMed  CAS  Google Scholar 

  4. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061

    Article  PubMed  CAS  Google Scholar 

  5. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

    Article  PubMed  CAS  Google Scholar 

  6. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397

    Article  PubMed  CAS  Google Scholar 

  7. Thiele J, Kvasnicka HM, Orazi A et al (2008) Polycythaemia vera. In: Swerdlow SH et al (eds) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon

    Google Scholar 

  8. Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459–468

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Pietra D, Li S, Brisci A et al (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111:1686–1689

    Article  PubMed  CAS  Google Scholar 

  10. Williams DM, Kim AH, Rogers O et al (2007) Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 35:1641–1646

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Verstovsek S (2009) Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009:636–642

    Article  Google Scholar 

  12. Steensma DP (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 8:397–411

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Levine RL, Pardanani A, Tefferi A et al (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673–683

    Article  PubMed  CAS  Google Scholar 

  14. Warshawsky I, Mularo F, Hren C et al (2010) Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V ?> ?F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C ?> ?F mutation in addition to 617V ?> ?F. Blood 115:3175–3176

    Article  PubMed  CAS  Google Scholar 

  15. Kiladjian JJ, Cassinatt B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037–2040

    Article  PubMed  CAS  Google Scholar 

  16. Vannucchi AM, Antonioli E, Guglielmelli P et al (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22:1299–1307

    Article  PubMed  CAS  Google Scholar 

  17. Passamonti F, Rumi E (2009) Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 94:7–10

    Article  PubMed  PubMed Central  Google Scholar 

  18. Marshall JJ, Halford SE (2010) The type IIb restriction endonucleases. Biochem Soc Trans 38:410–416

    Article  PubMed  CAS  Google Scholar 

  19. Wernig G, Kharas MG, Okabe R et al (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311–320

    Article  PubMed  CAS  Google Scholar 

  20. Parganas E, Wang D, Stravopodis D et al (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385–395

    Article  PubMed  CAS  Google Scholar 

  21. Albiero E, Madeo D, Ruggeri M et al (2008) Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modeling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis. Br J Haematol 142:986–990

    Article  PubMed  CAS  Google Scholar 

  22. Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:1140–1151

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA

    John A. Thorson & Huan-You Wang

  2. Molecular Diagnostics Laboratory, University of California San Diego Medical Center, 9500 Gilman Drive, #0639, La Jolla, CA, 92093, USA

    John A. Thorson

Authors
  1. John A. Thorson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huan-You Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John A. Thorson .

Editor information

Editors and Affiliations

  1. , Department of Pathology, Stanford University School of Medicine, Pasteur Drive 300, Stanford, 94305, California, USA

    Iris Schrijver

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Thorson, J.A., Wang, HY. (2011). Myeloproliferative Neoplasms. In: Schrijver, I. (eds) Diagnostic Molecular Pathology in Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19677-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-19677-5_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-19676-8

  • Online ISBN: 978-3-642-19677-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation